AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Summary

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.

Eligibility

Inclusion Criteria:

* Age ≥ 18 years (or ≥ 20 years if required by local regulation) at time of signing Informed Consent Form
* Previously treated with at least one ALK-TKI regardless of prior chemotherapy treatment (Patients who have received only crizotinib as prior ALK-TKI treatment will not be allowed.)
* Histologically or cytologically (excluding sputum cytology) proven diagnosis of locally advanced unresectable or metastatic ALK-positive NSCLC
* Measurable disease per RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Ability and willingness to take oral medication(s)
* Adequate organ function and bone marrow reserve

Exclusion Criteria:

* Prior toxicities from anti-cancer therapy which have not resolved to Grade ≤ 1 per NCI CTCAE v5.0 excluding alopecia, vitiligo, or endocrinopathies manageable with replacement therapy
* Symptomatic, active CNS metastases or untreated CNS metastases requiring any definitive therapy.
* Severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or renal disease, or active infection), or with a history or complication of interstitial lung disease
* Significant cardiovascular disease
* Inadequately controlled hypertension

Conditions3

Interventions2

Related trials

• A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib — Centro di Riferimento Oncologico - Aviano
• Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context — Pfizer
• Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients — Sichuan Cancer Hospital and Research Institute
• The Drug Rediscovery Protocol (DRUP Trial) — The Netherlands Cancer Institute
• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) — Children's Oncology Group
• Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion — Nationwide Children's Hospital
• Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer — M.D. Anderson Cancer Center
• Study of NXP900 With Lorlatinib in ALK+ Lung Cancer — Nuvectis Pharma, Inc.

Browse More Trials